Business Wire

Loop Energy Enters Agreement With NGVI to Supply Hydrogen Fuel Cell Systems for Transit Buses in South Korea With First Purchase Order Placed

17.8.2021 15:00:00 EEST | Business Wire | Press release

Share

Loop Energy (TSX:LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces the placement of the order for the first eFlow™ powered Hydrogen Fuel Cell Systems under a commercial agreement with NGVI, a South Korean-based manufacturer of turn-key compressed natural gas and hydrogen fuel systems for transit and coach bus applications. This announcement is an important milestone for Loop Energy as it signifies accelerating adoption of the eFlow™ fuel cell platform within the transit bus market vertical as well as Loop Energy’s official entry into the highly dynamic zero-emission commercial vehicle market in South Korea.

Under the agreement, Loop Energy will supply NGVI with the latest generation of its hydrogen fuel cell system offering featuring a fully integrated package of fuel cell module, cooling system and DCDC power conditioning equipment. NGVI is well positioned as a supplier within the South Korean bus market, with Seoul Bus company and TCHA Partners having a share of ownership in NGVI.

“With Loop’s state-of-the-art technology and NGVI’s system integration expertise and customer network, we believe we can make hydrogen electric transit a reality in South Korea and beyond,” said Ben Nyland, President and Chief Executive Officer of Loop Energy. “Our fully integrated fuel cell system product line incorporates a lot of the input we collected from the customers, and the performance has been nothing short of outstanding. From the field data rolling in daily from previously announced municipal bus fleet in Nanjing, China, to new customer engagements in Eastern Europe and now in Korea, we are very pleased with the success we had in the transit bus market over the last few months.”

The first hydrogen fuel cell system supplied under the agreement is earmarked for construction of the first testing and homologation vehicles under the agreement signed between NGVI and Ulsan Metropolitan City for supply of hydrogen electric transit buses. Under the first phase of the multi-year agreement, Ulsan is anticipated to invest 2.3 billion KRW (approximately $2.0 million USD) by 2024 in testing and certification of hydrogen bus technologies, supplied by a consortium of partners including NGVI. Ulsan announced a plan in 2018 to replace 40% of the city’s 949 buses with hydrogen-fueled vehicles and establish 60 hydrogen fueling stations by 2030.

After development and demonstration, the buses are expected to expand to fleet used in the capital area where Seoul Bus Company and TCHA Partners own over 1,200 buses. The city says demand will rise as approximately 10 percent of Seoul buses are replaced or decommissioned annually. The number of buses owned by them is expected to be more than 2,000 by 2023, and the demand in the metropolitan area is expected to be more than 200 per year.

“The future of bus transit fleet depends on hydrogen fuel cell technology, and we are extremely pleased to kick off the project with NGVI,” said Hyun Tae Hwang, Head Researcher at Ulsan Technopark that actually leads the project by consignment from Ulsan City. “To make the economics work, fuel efficiency is important to us because it is the largest share of our total operating cost, and we are committed to using the vehicles equipped with most advanced hydrogen fuel cell systems that NGVI can supply.”

“Our major shareholders include some of Korea’s largest bus fleet operators. As a result, we have a unique level of appreciation for the impact vehicle’s cost of ownership has on how quickly South Korea’s bus transit with adopting hydrogen technology,” said David Jung, Chief Executive Officer of NGVI. “We have chosen to partner with Loop Energy because their products combine performance and economics into one value proposition that gives fleet operators exactly what they want.”

About NGVI

NGVI (Natural Gas Vehicles International) is a South-Korea based company specializing in the first compressed natural gas fuel storage and supply system modules. Founded in 2000, NGVI is an IATF 16949 certified company and provides 2,000 modules per year to its customers. In addition to natural gas vehicles, NGVI also assists with the design, development and manufacturing of fuel storage and supply systems for hydrogen vehicles and are planning to extend their services to other areas of transportation, including trains and ships. www.ngvi.co.kr

About Loop Energy Inc.

Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including, light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop’s products feature the Company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow™ was designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.

This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the ability of the Company to execute on its strategy and the factors discussed under “Risk Factors” in the final long-form prospectus of the Company dated February 18, 2021. Loop disclaims any obligation to update these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Loop Energy Media: Ashley Eisner | +1.212.697.2600 | aeisner@gscommunications.com
Loop Energy Business: George Rubin | +1.604.828.8185 | grubin@loopenergy.com
NGVI Business: David Jung | +82.33.260.3478 | david.jung@ngvi.co.kr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye